ClinicalTrials.gg
CompletedNCT01948830TRENDUpdated Apr 17, 2017Results posted

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

A Phase 3 interventional study of Ranibizumab 0.5mg and Ranibizumab 0.5mg in Age-related Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis Pharmaceuticals. Completed at 91 sites in 19 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
650
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
11th of 124
650 · median 64
Started
2013
with 8 others
Phase 3
31 of 125
2 open now
Registered
79th of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 11th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2013, is one of 31 in phase 3, and was the 79th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration

Read the detailed description

This was a 12-month, phase IIIb, randomized, Visual Acuity assessor-masked, multi-center, interventional study assessing the efficacy and safety of the TER vs monthly regimens of 0.5 mg ranibizumab intravitreal (IVT) injections in patients with newly diagnosed nAMD. Patients will be randomized 1:1 into one of two treatment arms, Treat and Extend or monthly regimens.

There will be 3 periods in this study: Screening period (up to 14days), treatment period (11 months), follow-up period (1 month). At randomization visit patients will be randomized into one of the 2 treatment groups Group I ranibizumab 0.5 mg based on monthly treatment or Group II ranibizumab 0.5 mg based on TER (randomization ratio of 1:1) and will receive the first dose of Investigational treatment. Patients in Group I the following visits will perform on monthly intervals. For patients in Group II the investigator will evaluate disease activity (i.e., signs of exudation) based on SD-OCT, and in case of absence of disease activity every next visit will be 2 weeks), with a maximum of a 12-week interval.

03

Conditions studied

  • Age-related Macular Degeneration
  • Choroidal Neovascularization

Keywords

  • Ranibizumab, Lucentis, choroidal neovascularization, age-related macular degeneration, treat and extend regimen
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female patients, ≥50 years of age with signed before study procedures
  • Visual impairment predominantly due to nAMD.
  • Active CNV secondary to AMD confirmed by presence of active leakage from CNV seen by fluorescein angiography (FA) and/or color fundus photography
  • Presence of intra- or subretinal fluid/hemorrhage seen by SD-OCT
  • BCVA score must be ≤ 78 and ≥ 23 letters at 4 meters starting distance using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity charts (approximate Snellen equivalent of 20/32 and 20/320)

Key Exclusion Criteria:

  • Any type of advanced, severe or unstable disease, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.
  • Stroke or myocardial infarction within 3 months prior to Screening.
  • Any active periocular or ocular infection or inflammation in both eyes.
  • Ocular disorders in the study eye at the time of enrollment that may confound interpretation of study results and compromise visual acuity.
  • Presence of amblyopia or amaurosis in the fellow eye.
  • History of treatment with any anti-angiogenic drugs (including any anti- vascular endothelial growth factor (anti-VEGF) agents) e.g., bevacizumab [Avastin®], aflibercept [Eylea®]) or vPDT in the study eye.
  • History of intravitreal treatment with within 6 months and history of intra-ocular surgery within 3 months in the study eye prior to the Screening.
  • Pregnant or nursing (lactating) women. Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing of study treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
650 participants (actual)

Study arms

  • Active comparator
    Group I ranibizumab 0.5 mg monthly

    Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11

    Drug: Ranibizumab 0.5mg

  • Active comparator
    Group II ranibizumab 0.5 mg TER

    Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11

    Drug: Ranibizumab 0.5mg

Interventions

  • 0.5 mg ranibizumab (intravitreal injections) prefilled syringe)

    Also known as: Lucentis

  • 0.5 mg ranibizumab (intravitreal injections) prefilled syringe)

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement

    Time frame: Baseline to month 12

Secondary outcomes

  1. Number of Visits Scheduled

    The number of visits scheduled according to the treat and extend regimen after treatment initiation

    Time frame: From Month1 to Month 11

  2. Change in BCVA From Baseline to Month 12

    Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters

    Time frame: Baseline to Month 12

  3. Average BCVA Change From Baseline to Month 12

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12

    Time frame: Baseline and every month for 12 months

  4. Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline

    Time frame: Baseline and every month for 12 months

  5. Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline

    Time frame: Baseline and every month for 12 months

  6. Number of Patients With Best Corrected Visual Acuity (BCVA) Loss <5, <10, and <15 Letters by Visit

    Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.

    Time frame: Baseline and every month for 12 months

  7. Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12

    Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome

    Time frame: Baseline and every month for 12 months

  8. The Mean Number of Treatment Frequency

    The number of injections received

    Time frame: Month 12

  9. The Average Number of Days Between Injections

    The average dosing interval was measured as the average number of days between injections

    Time frame: Month 12

  10. Percentage of Participants With Fluid Free Macula Over Time up to Month 12

    OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages

    Time frame: Month 12

  11. Change in Central Subfield Retinal Thickness (CSFT) Over Time

    OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit

    Time frame: Month 12

  12. Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at

    To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.

    Time frame: Month 12

  13. Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)

    The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome

    Time frame: Baseline, Month 12

07

Results

Posted Dec 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Started323327
Safety set323326
Completed290295
Not completed3332
Withdrew: Physician decision13
Withdrew: Protocol deviation12
Withdrew: Lost to follow-up54
Withdrew: Withdrawal by subject1417
Withdrew: Adverse event92
Withdrew: Death34

Outcome measures

PrimaryChange in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement

Time frame:
Baseline to month 12
Reported as:
Least squares mean · Letters (EDTRS)
Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12
Letters (EDTRS)Group I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 126.2 ± 0.708.1 ± 0.70
Statistical analysis
  • Group I Ranibizumab 0.5 mg TER vs Group II Ranibizumab 0.5 mg Monthly · ANCOVA · p = <0.001
SecondaryNumber of Visits Scheduled

The number of visits scheduled according to the treat and extend regimen after treatment initiation

Time frame:
From Month1 to Month 11
Reported as:
Mean · Number of visits
Number of Visits Scheduled
Number of visitsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Number of Visits Scheduled8.9 ± 2.5611.2 ± 2.37
SecondaryChange in BCVA From Baseline to Month 12

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters

Time frame:
Baseline to Month 12
Reported as:
Mean · Letters (EDTRS)
Change in BCVA From Baseline to Month 12
Letters (EDTRS)Group I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Change in BCVA From Baseline to Month 126.4 ± 14.118.0 ± 11.61
SecondaryAverage BCVA Change From Baseline to Month 12

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters. Mean Visual Acuity was averaged over all monthly assessments from Baseline to Month 12

Time frame:
Baseline and every month for 12 months
Reported as:
Mean · Letters (EDTRS)
Average BCVA Change From Baseline to Month 12
Letters (EDTRS)Group I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Average BCVA Change From Baseline to Month 126.3 ± 10.507.1 ± 9.41
SecondaryMean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS) -like charts while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. For the mean change of best corrected visual acuity at Month 12 and compare to Baseline

Time frame:
Baseline and every month for 12 months
Reported as:
Mean · Letters (EDTRS)
Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12
Letters (EDTRS)Group I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Month 1 (n=320, 322)4.6 ± 7.564.2 ± 6.98
Month 2 (n=240, 316)5.5 ± 8.645.8 ± 8.58
Month 3 (n=247, 311)6.7 ± 9.096.7 ± 9.19
Month 4 (n=213, 314)7.0 ± 10.907.3 ± 9.95
Month 5 (n=231, 302)6.0 ± 11.347.7 ± 10.61
month 6 (n=205, 302)6.9 ± 13.347.9 ± 10.83
Month 7 (n=230, 298)5.9 ± 14.257.9 ± 11.36
Month 8 (n=210, 295)7.5 ± 12.877.9 ± 11.34
Month 9 (n=179, 295)6.6 ± 13.637.6 ± 12.56
Month 10 (n=202, 296)6.3 ± 13.447.6 ± 12.06
Month 11 (n=180, 290)5.9 ± 14.127.5 ± 12.48
Month 12 (n=294, 295)6.6 ± 13.417.9 ± 11.96
SecondaryNumber of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the number of participants who had improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters of visual acuity at Month 12 as compared with baseline

Time frame:
Baseline and every month for 12 months
Reported as:
Number · Number of participants
Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12
Number of participantsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Month 1,Gain of ≥ 1 letter (n=320,322)235233
Month 1, Gain of ≥ 5 letters145145
Month 1, Gain of ≥ 10 letters6558
Month 1, Gain of ≥ 15 letters2423
Month 1, Gain of ≥ 30 letters42
Month 2, Gain of >= 1 letter (n=226, 316)168244
Month 2, Gain of >= 5 letters123184
Month 2, Gain of >= 10 letters6088
Month 2, Gain of >= 15 letters3039
Month 2, Gain of >= 30 letters43
Month 3, Gain of >= 1 letter (n=161,311)120244
Month 3, Gain of >= 5 letters98187
Month 3, Gain of >= 10 letters57110
Month 3, Gain of >= 15 letters2846
Month 3, Gain of >= 30 letters23
Month 4, Gain of >= 1 letter (n=128, 314)96249
Month 4, Gain of >= 5 letters67198
Month 4, Gain of >=10 letters48118
Month 4, Gain of >= 15 letters2560
Month 4, Gain of >= 30 letters48
Month 5, Gain of >= 1 letter (n=114, 302)84243
Month 5, Gain of >= 5 letters64197
Month 5, Gain of >= 10 letters42116
Month 5, Gain of >= 15 letters1959
Month 5, Gain of >= 30 letters310
Month 6, Gain of >= 1 letter (n=117, 302)85238
Month 6, Gain of >= 5 letters68197
Month 6, Gain of >= 10 letters42125
Month 6, Gain of >= 15 letters1961
Month 6, Gain of >= 30 letters211
Month 7, Gain of >= 1 letter (n=176, 298)126235
Month 7, Gain of >= 5 letters94196
Month 7, Gain of >= 10 letters57123
Month 7, Gain of >= 15 letters3369
Month 7, Gain of >= 30 letters79
Month 8, Gain of >= 1 letter (n=163, 295)124228
Month 8, Gain of >= 5 letters108198
Month 8, Gain of >= 10 letters69130
Month 8, Gain of >= 15 letters4072
Month 8, Gain of >= 30 letters49
Month 9, Gain of >= 1 letter (n=129, 295)93229
Month 9, Gain of >= 5 letters78186
Month 9, Gain of >= 10 letters52128
Month 9, Gain of >= 15 letters2870
Month 9, Gain of >= 30 letters58
Month 10, Gain of >= 1 letter (n=159, 296)113230
Month 10, Gain of >= 5 letters98190
Month 10, Gain of >= 10 letters60126
Month 10, Gain of >= 15 letters3274
Month 10, Gain of >= 30 letters410
Month 11, Gain of >= 1 letter (131, 290)94222
Month 11, Gain of >= 5 letters79187
Month 11, Gain of >= 10 letters51130
Month 11, Gain of >= 15 letters3274
Month 11, Gain of >= 30 letters59
Month 12, Gain of >= 1 letter (n=291, 295)217226
Month 12, Gain of >= 5 letters178199
Month 12, Gain of >= 10 letters123135
Month 12, Gain of >= 15 letters7577
Month 12, Gain of >= 30 letters128
SecondaryNumber of Patients With Best Corrected Visual Acuity (BCVA) Loss <5, <10, and <15 Letters by Visit

Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.Best Corrected Visual Acuity (BCVA) was assessed in a sitting position using ETDRS-like visual acuity testing charts at an initial testing distance of 4 meters.

Time frame:
Baseline and every month for 12 months
Reported as:
Number · Number of participants
Number of Patients With Best Corrected Visual Acuity (BCVA) Loss <5, <10, and <15 Letters by Visit
Number of participantsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Month 1, Loss of < 5 letters (n=320, 322)296295
Month 1, Loss of < 10 letters313314
Month 1, Loss of < 15 letters319320
Month 2, Loss of < 5 letters (n=226, 316)205288
Month 2, Loss of < 10 letters220306
Month 2, Loss of < 15 letters223309
Month 3, Loss of < 5 letters (n=161, 311)146289
Month 3, Loss of < 10 letters158299
Month 3, Loss of < 15 letters160304
Month 4, Loss of < 5 letters (n=128, 314)114286
Month 4, Loss of < 10 letters128301
Month 4, Loss of < 15 letters124307
Month 5, Loss of < 5 letters (n=114, 302)97276
Month 5, Loss of < 10 letters105287
Month 5, Loss of < 15 letters108295
Month 6, Loss of < 5 letters (n=117, 302)104271
Month 6, Loss of < 10 letters110286
Month 6, Loss of < 15 letters111298
Month 7, Loss of < 5 letters (n=176, 298)148268
Month 7, Loss of < 10 letters162279
Month 7, Loss of < 15 letters166289
Month 8, Loss of < 5 letters (n=163, 295)145262
Month 8, Loss of < 10 letters155276
Month 8, Loss of < 15 letters155286
Month 9, Loss of < 5 letters (n=129, 295)110258
Month 9, Loss of < 10 letters120270
Month 9, Loss of < 15 letters122281
Month 10, Loss of < 5 letters(n=159, 296)133253
Month 10, Loss of < 10 letters147276
Month 10, Loss of < 15 letters150285
Month 11, Loss of < 5 letters (n=131, 290)105251
Month 11, Loss of < 10 letters118263
Month 11, Loss of < 15 letters121275
Month 12, Loss of < 5 letters (291, 295)247256
Month 12, Loss of < 10 letters267272
Month 12, Loss of < 15 letters273284
SecondaryNumber of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12

Best Corrected Visual Acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at baseline and month 12 while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. BCVA above 73 letters at Month 12 indicates a positive outcome

Time frame:
Baseline and every month for 12 months
Reported as:
Number · Number of participants
Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12
Number of participantsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Month 1 (n=320, 322)106106
Month 2 (n=226, 316)74136
Month 3 (n=161, 311)67148
Month 4 (n=128, 314)60147
Month 5 (n=114, 302)51156
Month 6 (n=117, 302)58155
Month 7 (n=176, 298)78150
Month 8 (n=163, 295)84155
Month 9 (n=129, 295)68156
Month 10 (n=159, 296)74149
Month 11 (n=131, 29063143
Month 12 (n=291, 295)131149
SecondaryThe Mean Number of Treatment Frequency

The number of injections received

Time frame:
Month 12
Reported as:
Mean · Number of injections
The Mean Number of Treatment Frequency
Number of injectionsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
The Mean Number of Treatment Frequency8.7 ± 2.6811.0 ± 2.50
SecondaryThe Average Number of Days Between Injections

The average dosing interval was measured as the average number of days between injections

Time frame:
Month 12
Reported as:
Mean · days
The Average Number of Days Between Injections
daysGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
The Average Number of Days Between Injections40.3 ± 11.2829.4 ± 3.27
SecondaryPercentage of Participants With Fluid Free Macula Over Time up to Month 12

OCT (optical coherence tomography) was used to assess intra-retinal fluid as Measured by SD-OCT (Spectral Domain-Optical Coherence Tomography). Fluid free macula refers to absence of macular edema (as assessed by the reading center). The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the macular edema (center involvement) at study completion. These total counts are used as the denominator for the percentages

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Fluid Free Macula Over Time up to Month 12
Percentage of participantsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Absent60.560.7
Definite39.539
Can't grade0.00.3
SecondaryChange in Central Subfield Retinal Thickness (CSFT) Over Time

OCT (optical coherence tomography) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit

Time frame:
Month 12
Reported as:
Mean · microns
Change in Central Subfield Retinal Thickness (CSFT) Over Time
micronsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Month 1 (n=311, 316)-137.6 ± 132.33-126.8 ± 119.47
Month 2 (n=220, 311)-151.6 ± 151.15-149.2 ± 137.60
Month 3 (n=157, 304)-149.8 ± 167.26-151.8 ± 149.51
Month 4 (n=125, 307)-141.8 ± 183.71-161.3 ± 149.36
Month 5 (n=110, 295)-138.6 ± 160.04-160.9 ± 148.23
Month 6 (n=113, 298)-140.1 ± 156.25-163.4 ± 157.18
Month 7 (n=173, 296)-146.6 ± 160.72-166.9 ± 161.49
Month 8 (n=159, 290)-153.4 ± 151.93-170.4 ± 156.68
Month 9 (n=126, 286)-150.2 ± 153.82-169.3 ± 156.50
Month 10 (n=156, 291)-154.6 ± 162.77-170.9 ± 153.90
Month 11 (n=127, 285)-133.1 ± 170.47-174.8 ± 163.16
Month 12 (n=289, 287)-172.1 ± 162.81-173.3 ± 154.13
SecondaryPercentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at

To evaluate presence of active CNV leakage on fluorescein angiography (FA) by reading center over time up to Month 12. The full analysis set was used for this evaluation but the count presented are the counts of patients in the specific treatment group who have a value for the presence of leakage at study completion. These total counts are used as the denominator for the percentages.

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the Study Eye at
Percentage of participantsGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Yes18.717.1
No74.176.9
Can't grade0.02.4
Not applicable7.23.5
SecondaryChange From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)

The survey consisted of 25 items representing 11 vision related constructs (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, color vision, peripheral vision) plus a single-item general health rating question. The score of each individual question ranged from 0 (worst) to 100 which indicates the best possible response. The composite score and score of each of each construct also ranged from 0 to 100 as they are calculated as total scores divided by the number of questions. The higher the values of total scores represent better outcome

Time frame:
Baseline, Month 12
Reported as:
Mean · Score on a scale
Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)
Score on a scaleGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25)2.3 ± 13.934 ± 13.72

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group I Ranibizumab 0.5 mg TER—39/323 (12.1%)164/323 (50.8%)
Group II Ranibizumab 0.5 mg Monthly—42/326 (12.9%)166/326 (50.9%)
Most frequent serious events
Showing 10 of 103
Most frequent serious events
EventGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
PneumoniaInfections and infestations4/3232/326
Transient ischaemic attackNervous system disorders3/3231/326
Myocardial infarctionCardiac disorders2/3230/326
VertigoEar and labyrinth disorders2/3230/326
BronchitisInfections and infestations2/3230/326
Femur fractureInjury, poisoning and procedural complications2/3230/326
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/3231/326
DyspnoeaRespiratory, thoracic and mediastinal disorders2/3231/326
HypotensionVascular disorders2/3230/326
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3232/326
Most frequent other events
Showing 10 of 45
Most frequent other events
EventGroup I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg Monthly
Intraocular pressure increased (Study eye)Investigations27/32328/326
NasopharyngitisInfections and infestations18/32326/326
HypertensionVascular disorders23/32313/326
Conjunctival haemorrhage (Study eye)Eye disorders14/32319/326
Neovascular age-related macular degeneration (Fellow eye)Eye disorders8/32316/326
Visual acuity reduced (Study eye)Eye disorders15/32312/326
BronchitisInfections and infestations6/32312/326
InfluenzaInfections and infestations9/32312/326
Eye pain (Study eye)Eye disorders10/3235/326
Conjunctivitis (Study eye)Infections and infestations10/3236/326

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg MonthlyTotal
Mean75.3 ± 8.6175.2 ± 8.1375.2 ± 8.37
Sex: Female, Male
Sex: Female, Male(Participants)Group I Ranibizumab 0.5 mg TERGroup II Ranibizumab 0.5 mg MonthlyTotal
Female179181360
Male144146290
08

Study locations

91 sites
  • Novartis Investigative Site
    Antwerpen, 2020, Belgium
  • Novartis Investigative Site
    Ottignies, 1340, Belgium
  • Novartis Investigative Site
    Zottegem, 9620, Belgium
  • Novartis Investigative Site
    Santiago, 7650018, Chile
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Glostrup, 2600, Denmark
  • Novartis Investigative Site
    Roskilde, 4000, Denmark
  • Novartis Investigative Site
    Cairo, Abbassia, Egypt
  • Novartis Investigative Site
    Cairo, Egypt
  • Novartis Investigative Site
    Ahaus, 48683, Germany
  • Novartis Investigative Site
    Augsburg, 86156, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Darmstadt, 64297, Germany
  • Novartis Investigative Site
    Göttingen, 37075, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Karlsruhe, 76199, Germany
  • Novartis Investigative Site
    Koeln, 50935, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Ludwigshafen, 67063, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Muenster, 48145, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Siegburg, 53721, Germany
  • Novartis Investigative Site
    Stuttgart, 70174, Germany
  • Novartis Investigative Site
    Sulzbach, 66280, Germany
  • Novartis Investigative Site
    Budapest, 1076, Hungary
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Budapest, 1106, Hungary
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Budapest, 1145, Hungary
  • Novartis Investigative Site
    Budapest, H-1115, Hungary
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Pécs, 7624, Hungary
  • Novartis Investigative Site
    Szeged, H-6725, Hungary
  • Novartis Investigative Site
    Zalaegerszeg, 8900, Hungary
  • Novartis Investigative Site
    Bangalore, Karnataka 560010, India
  • Novartis Investigative Site
    Chennai, Tamil Nadu 600 006, India
  • Novartis Investigative Site
    Vanchiyoor, Thiruvanantapuram 695035, India
  • Novartis Investigative Site
    Haifa, 3525408, Israel
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Petach Tikva, 49100, Israel
  • Novartis Investigative Site
    Rehovot, 76100, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Milano, MI 20100, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Pisa, PI 56124, Italy
  • Novartis Investigative Site
    Roma, RM 00198, Italy
  • Novartis Investigative Site
    Sassari, SS 07100, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Seongnam, Gyeonggi 13620, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 06591, Korea, Republic of
  • Novartis Investigative Site
    Busan, 49241, Korea, Republic of
  • Novartis Investigative Site
    Coimbra, 3000-354, Portugal
  • Novartis Investigative Site
    Coimbra, 3030-163, Portugal
  • Novartis Investigative Site
    Lisboa, 1150-314, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Vila Franca de Xira, 2600-009, Portugal
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Moscow, 119021, Russian Federation
  • Novartis Investigative Site
    Moscow, 127486, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, 630071, Russian Federation
  • Novartis Investigative Site
    Samara, 443068, Russian Federation
  • Novartis Investigative Site
    Banska Bystrica, 97517, Slovakia
  • Novartis Investigative Site
    Bratislava, 82606, Slovakia
  • Novartis Investigative Site
    Nove Zamky, 94001, Slovakia
  • Novartis Investigative Site
    Poprad, 05845, Slovakia
  • Novartis Investigative Site
    Zilina, 01207, Slovakia
  • Novartis Investigative Site
    Ljubljana, 1000, Slovenia
  • Novartis Investigative Site
    Oviedo, Asturias 33012, Spain
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47011, Spain
  • Novartis Investigative Site
    Sant Cugat, Catalunya 08190, Spain
  • Novartis Investigative Site
    Barcelona, Cataluña 08022, Spain
  • Novartis Investigative Site
    Barcelona, 08025, Spain
  • Novartis Investigative Site
    Zaragoza, 50009, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Bern, 3012, Switzerland
  • Novartis Investigative Site
    Lausanne, 1007, Switzerland
  • Novartis Investigative Site
    Zuerich, 8063, Switzerland
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06490, Turkey
  • Novartis Investigative Site
    Uxbridge, London UB8 3NN, United Kingdom
  • Novartis Investigative Site
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Belfast, BT12 6BA, United Kingdom
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
  • Novartis Investigative Site
    Guildford, Surrey, GU2 5XX, United Kingdom
  • Novartis Investigative Site
    London, EC1V 2PD, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Sunderland, SR2 9HP, United Kingdom
09

References and documents

Publications

  • Pawloff M, Bogunovic H, Gruber A, Michl M, Riedl S, Schmidt-Erfurth U. SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES. Retina. 2022 May 1;42(5):831-841. doi: 10.1097/IAE.0000000000003385. PubMed 34934034 ↗
  • Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2. PubMed 32374423 ↗
  • Waldstein SM, Coulibaly L, Riedl S, Sadeghipour A, Gerendas BS, Schmidt-Erfurth UM. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration. Br J Ophthalmol. 2020 Jul;104(7):899-903. doi: 10.1136/bjophthalmol-2019-314661. Epub 2019 Sep 28. PubMed 31563866 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Nov 2015, 23 months.

Results were first posted in Dec 2016, 1 year after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 23 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2013
First posted
Sep 24, 2013
StartActual
Dec 17, 2013
Primary completionActual
Nov 19, 2015
CompletionActual
Nov 19, 2015
Results first posted
Dec 15, 2016
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01948830
Responsible party
Sponsor
First posted
Sep 24, 2013
Start date
Dec 17, 2013
Primary completion
Nov 19, 2015
Completion
Nov 19, 2015
Results posted
Dec 15, 2016
Last update
Apr 17, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion